Tianjin Chasesun Pharmaceutical Co., Ltd.
红日药业
300026
Shenzhen Stock Exchange
Company Profile
1. As for the TCM formula granules business, during the reporting period, the company continued to accelerate the development, application, and filing of national and provincial standards for TCM formula granules to further expand the coverage of product varieties across regions and enhance market competitiveness. Meanwhile, the company advanced academic marketing and brand building, expanded terminal coverage and channel penetration, and enhanced customer service capabilities. These efforts enabled the company to actively respond to the quality improvement and expanded implementation of centralized procurement for formula granules and capture market opportunities. 2. As for the finished drug products business, during the reporting period, the project titled "Key Technologies for Safety Evaluation and Promotion of Combined Use of Traditional Chinese Medicine Injections" won the 2025 Science and Technology Award of the Chinese Association of Integrative Medicine, one of the most influential awards in the field. This recognition provides solid scientific support for rational clinical medication use. New specifications of Sarpogrelate Hydrochloride Tablets and Anruotai (soft-bag formulation) were rapidly launched, further enriching the company's product portfolio. Additionally, Thymalfasin for Injection passed the quality and efficacy consistency evaluation for generic injections, providing valuable experience for the subsequent development and consistency evaluation of other generic products. A study on Xuebijing Injection was published in a Lancet-family journal, precisely revealing its differentiated therapeutic benefits in patients with different sepsis subtypes. The study enabled precision treatment based on clinical phenotypes, provided a Chinese solution for personalized intervention in sepsis, and supported performance growth. 3. As for the medical devices business, during the reporting period, the project "Lightweight Intelligent Multi-parameter Detector Based on Multimodal Biosignals and AI-driven Technology" was successfully shortlisted for the Ministry of Industry and Information Technology's 2025 AI Medical Device Innovation Task Shortlist. The invention patent application filed by Tianjin ChoiceMMed, "A Method and Device for Measuring Respiratory Rate Based on PPG Signals", received the 2025 Tianjin Patent Excellence Award. In addition, the multi-parameter telemetry monitoring system obtained the Medical Device Registration Certificate, further enriching the company's product portfolio. Lanzhou Wenhe, a holding subsidiary of the company, advanced five patent authorization applications and completed the registration change for its "Disposable Nasal Oxygen Cannula". By strengthening technical reserves and continuously expanding product offerings, it drove the sustainable development of this business segment. 4. As for the drug substances and excipients business, during the reporting period, Zhanwang Pharmaceutical, a wholly-owned subsidiary of the company, successfully completed the renewal registration of three drug substances, namely dibasic calcium phosphate, methotrexate, and calcium folinate. It also submitted filing application materials for two excipients, N-methyl-2-pyrrolidone and hypromellose acetate succinate. The inspection-exemption application for the compound coating agent for food additives passed review and the product officially entered production. In addition, the drug substance iron protein succinylate passed the associated review by the Center for Drug Evaluation of the NMPA, marking new progress in drug registration and compliance, and further optimizing the company's product structure. Meanwhile, Zhanwang Pharmaceutical successfully passed the re-evaluation as a national-level specialized, sophisticated, distinctive and innovative "Little Giant" enterprise. Enoray, a holding subsidiary of the company, received a certificate from the China Biochemical Pharmaceutical Industry Association for participating in the drafting of the Guidelines for Pharmaceutical Research and Technical Evaluation of Generic Low-Molecular-Weight Heparin Drugs. Additionally, it passed the U.S. Food and Drug Administration (FDA) on-site cGMP inspection with zero Form 483 observations and was recognized as a Hubei Province Manufacturing Single Champion Enterprise. 5. As for the healthcare services business, during the reporting period, the company's intelligent remote healthcare model was successfully implemented, achieving breakthroughs in partnerships with chain pharmacies and promoting large-scale expansion through joint operations. It also explored, for the first time, a new cooperation model with public hospitals by establishing a mutually beneficial entrusted operation model integrating internet hospital development, intelligent remote system empowerment, and private-domain operations and conversion, thereby driving business growth. For its offline clinics, the company developed pediatric ADHD as a specialty area, with 10 clinics obtaining medical insurance designation. At the same time, it promoted cost reduction and efficiency improvement in clinic operations, thereby enhancing the overall economic performance of the healthcare services business. 6. As for the intelligent pharmaceutical and medical device supply chain business, during the reporting period, the company strengthened compliance management, enhanced full-level operational monitoring across its business operations, directed advantageous resources toward its core businesses, and promoted business optimization and upgrading.
Full description
The company's business operations are primarily organized into six segments: TCM formula granules, finished drug products, medical devices, drug substances and excipients, healthcare services, and intelligent pharmaceutical and medical device supply chain services, as detailed below: 1. As for the TCM formula granules business, Kangrentang "All-ingredients®" TCM formula granules represent a dosage-form reform of traditional TCM decoctions. Guided by the "All-ingredients®" concept and benchmarked against "standard decoctions", the company selects authentic crude drugs as raw materials, digitally characterizes traditional processing experience, and prepares decoction pieces using modern industrial equipment. Based on whole-process studies on quantity and quality transfer across extraction, concentration, drying, and preparation, the company achieves equivalence between formula granules and traditional decoctions in terms of "material basis" and consistency in "clinical efficacy". 2. As for the finished drug products business, the company follows an overall strategy centered on independent innovation and supplemented by a combination of generic and innovative drug development. By selecting optimal targets and product varieties, the company continues to strengthen its innovation and clinical capabilities, and promotes the application, development, and commercialization of new technologies, processes, and products. The company's main products include Xuebijing Injection, Fasudil Hydrochloride Injection, Low-Molecular-Weight Heparin Calcium Injection, Nadroparin Calcium Injection, Ketorolac Tromethamine Injection, Moxifloxacin Hydrochloride and Sodium Chloride Injection, Sodium Ibandronate Injection, Enoxaparin Sodium Injection, Qingfei Sanjie Pills, and Kang'aiping Pills. 3. As for the medical devices business, ChoiceMMed, a wholly-owned subsidiary of the company, focuses on electronic medical devices. Its business covers single-parameter and multi-parameter electronic medical devices and services in areas such as blood oxygen monitoring, home healthcare, and primary healthcare. Its product portfolio includes pulse oximeters, ECG monitors, blood pressure monitors, fetal heart monitors, thermometers, multi-parameter monitors, health checkup systems, all-in-one devices, intelligent oxygen concentrators, and portable oxygen concentrators. Wenhe Medical Devices, a holding subsidiary of the company, is mainly engaged in the R&D, production, and sales of medical devices related to medical polymer consumables, and is gradually expanding the development and promotion of food products based on medicine-food homology. 4. As for the drug substances and excipients business, the company actively promotes product optimization and process improvement through a R&D model combining independent innovation with industry-university-research collaboration. It is building an integrated R&D, production, and sales team to continuously enhance the core competitiveness of the business. 5. As for the healthcare services business, the company is committed to building a digital TCM services and industry empowerment platform. Adhering to the "whole-course" diagnosis and treatment strategy, the company continuously refines the diagnosis and treatment experience and improves access to high-quality TCM resources by building a closed-loop ecosystem consisting of its self-owned medicinal material supply chain, online platform, and offline clinics. 6. As for the intelligent pharmaceutical and medical device supply chain business, the company applies information technology and automated equipment to build an extended service platform for pharmaceutical and medical device supply chain and logistics, enabling digital management of the entire process from procurement through logistics to use.